ReveraGen BioPharma, based in Silver Spring, Md., is moving ahead with a phase 1 trial of an experimental compound in development to treat Duchenne muscular dystrophy, made possible by a $2 million grant from U.S.-based MDA and three United Kingdom-based DMD organizations. The drug, dubbed VBP15, will be evaluated for safety in healthy people in this phase 1 study.

Four nonprofit organizations, the Muscular Dystrophy Association (USA), Joining Jack Foundation (UK), The Duchenne Research Fund (UK) and the Duchenne Children’s Trust (UK) have joined together to provide Phase 1 clinical trial funding for the first-in-human studies of VBP15, the lead compound of ReveraGen BioPharma for Duchenne muscular dystrophy. The $2M funding is under a coordinated venture philanthropy model, providing return on investment based upon future drug sales.